- Price:
- EUR0.69
- Open:
- EUR0.75
- Previous close:
- EUR0.74
- Day's range:
- EUR0.69 - EUR0.79
- Year's range:
- EUR0.45 - EUR1.59
- Net Income per Share:
- -0.62
- Price-to-Earnings ratio:
- -1.12
- 52-week Price Range:
- EUR0.83
- Volume:
- EUR457,060.00
- Average volume:
- EUR1,166,760.00
Company profile for Novacyt S.A.
Novacyt S.A., is one of the leaders in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases. The company operates through three distinct segments, Primer Design, Lab21 Products, and IT-IS International.
Primer Design designs, develops and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. Their products are used in hospitals, labs, and other corporate establishments.
The Lab21 Products segment specializes in developing, manufacturing, and distributing a range of protein-based in-vitro diagnostic device products to detect infectious diseases.
IT-IS International is a segment that develops and manufactures PCR devices for both the life sciences and food testing industry.
Novacyt S.A. was founded in 2006 and is headquartered in Vélizy-Villacoublay, France. This European based company provides diagnostic products in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa.
Novacyt S.A. is guided by a team of professionals and has a robust business strategy and solid financials. They have won several awards in the field of diagnostic products and in 2020, the company was recognized by Frost & Sullivan with the 2021 Europe Molecular Diagnostics Company of the Year award. The company has also obtained two significant registrations for their flagship products Primerdesign and Lab21 Products. In 2020, their COVID-19 test, Research Use Only (RUO) RT-qPCR test for the detection of SARS-CoV-2, obtained the CE IVD mark, making it the first CE-IVD registered test to become available from a company with only European operations.
Novacyt S.A. continues to grow and innovate and provides consistent growth in its profits and revenue. In 2020, their revenue increased by 43% and their profits increased by 56%. In 2021, the company continues to launch new products and expand its markets and reach. The company is committed to maintaining the highest quality standards in its products and providing a safe, secure, and reliable product experience to its customers. Novacyt S.A. is well-positioned to continue its growth and remain a leader in the global diagnostic products industry.
- Stock exchanges:
- EURONEXT
- Sector:
- Healthcare
- Industries:
- Medical Devices
- Ticker:
- ALNOV.PA
- ISIN:
- FR0010397232
- Website:
- https://www.novacyt.com
- Phone:
- 33 1 39 46 51 04
- Origin:
- France
- Employees:
- 210